Literature DB >> 18220700

The toll of Toll-like receptors, especially toll-like receptor 2, on murine atherosclerosis.

L K Curtiss1, P S Tobias.   

Abstract

At one time, atherosclerosis was thought to be a simple lipid storage disease. However, it is now recognized as a chronic and progressive inflammation of the arterial wall. Gene deletion experiments in murine models of atherosclerosis that reduce the inflammatory process also reduce disease severity. Identifying the initiators and mediators of that inflammation can provide promising avenues for prevention or therapy. Two prominent risk factors, hyperlipidemia and infectious disease, point to innate immune mechanisms as potential contributors to proatherogenic inflammation. The Toll-like receptors (TLR), proinflammatory sensors of pathogens, are potential links between inflammation, infectious disease and atherosclerosis. There is increasing evidence that TLRs also recognize host-derived ligands and this also connects TLRs to diseases that may not have an etiology that is associated directly with infection. A mechanism for hyperlipidemic initiation of sterile inflammation can be postulated because oxidized lipoproteins or their component oxidized lipids have been identified as TLR ligands. Moreover, infectious agents are correlated with atherosclerosis risk. There are multiple published reports that TLR4 activation is relevant to the inflammation of atherosclerosis in mice and humans. In addition, we have identified a role for TLR2 in atherosclerosis in low density lipoprotein receptor-deficient (LDLr-/-) mice. Proatherogenic TLR2 responses to unknown endogenous or unknown endemic exogenous agonists are mediated by non-bone marrow-derived cells, which can include endothelial cells, adventitial fibroblasts and vascular smooth muscle cells. This is in contrast to the proatherogenic TLR2 response to defined synthetic exogenous agonists, which is mediated at least in part by bone marrow-derived cells, which can include lymphocytes, monocytes/macrophages, NK cells and dendritic cells. Thus, TLR2-mediated cell activation in response to endogenous and exogenous agents is proatherogenic in hyperlipidemic mice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18220700     DOI: 10.2174/138945007783220605

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  14 in total

1.  High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide.

Authors:  Masashi Suzuki; David K Pritchard; Lev Becker; Andrew N Hoofnagle; Natsuko Tanimura; Theo K Bammler; Richard P Beyer; Roger Bumgarner; Tomas Vaisar; Maria C de Beer; Frederick C de Beer; Kensuke Miyake; John F Oram; Jay W Heinecke
Journal:  Circulation       Date:  2010-10-25       Impact factor: 29.690

2.  Atherogenic high cholesterol/high fat diet induces TLRs-associated pulmonary inflammation in C57BL/6J mice.

Authors:  Yan Fang; Shuang Wang; Tingting Zhu; Yong Zhang; Xuemei Lian
Journal:  Inflamm Res       Date:  2016-09-21       Impact factor: 4.575

3.  Atherosclerosis induced by endogenous and exogenous toll-like receptor (TLR)1 or TLR6 agonists.

Authors:  Linda K Curtiss; Audrey S Black; David J Bonnet; Peter S Tobias
Journal:  J Lipid Res       Date:  2012-07-20       Impact factor: 5.922

Review 4.  Toll-like Receptors in the Vascular System: Sensing the Dangers Within.

Authors:  Styliani Goulopoulou; Cameron G McCarthy; R Clinton Webb
Journal:  Pharmacol Rev       Date:  2016-01       Impact factor: 25.468

5.  Blocking TLR2 activity diminishes and stabilizes advanced atherosclerotic lesions in apolipoprotein E-deficient mice.

Authors:  Xiao-xing Wang; Xiao-xi Lv; Jia-ping Wang; Hui-min Yan; Zi-yan Wang; Han-zhi Liu; Xiao-ming Fu; Zhuo-wei Hu
Journal:  Acta Pharmacol Sin       Date:  2013-07-15       Impact factor: 6.150

6.  The LPS2 mutation in TRIF is atheroprotective in hyperlipidemic low density lipoprotein receptor knockout mice.

Authors:  M Rachel Richards; Audrey S Black; David J Bonnet; Grant D Barish; Connie W Woo; Ira Tabas; Linda K Curtiss; Peter S Tobias
Journal:  Innate Immun       Date:  2012-05-25       Impact factor: 2.680

7.  TLR4 antagonist attenuates atherogenesis in LDL receptor-deficient mice with diet-induced type 2 diabetes.

Authors:  Zhongyang Lu; Xiaoming Zhang; Yanchun Li; Maria F Lopes-Virella; Yan Huang
Journal:  Immunobiology       Date:  2015-06-30       Impact factor: 3.144

Review 8.  Rheostatic signaling by CD44 and hyaluronan.

Authors:  Ellen Puré; Richard K Assoian
Journal:  Cell Signal       Date:  2009-01-13       Impact factor: 4.315

Review 9.  Inflammation and atherosclerosis: direct versus indirect mechanisms.

Authors:  Michael E Rosenfeld
Journal:  Curr Opin Pharmacol       Date:  2013-01-26       Impact factor: 5.547

Review 10.  Toll-like receptors and damage-associated molecular patterns: novel links between inflammation and hypertension.

Authors:  Cameron G McCarthy; Styliani Goulopoulou; Camilla F Wenceslau; Kathryn Spitler; Takayuki Matsumoto; R Clinton Webb
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-10-25       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.